Nplate, Romiplate (romiplostim) Market Report 2026

Nplate, Romiplate (romiplostim) Market Overview

• The Nplate, Romiplate (romiplostim) market growth in the historic period has been driven by limited treatment options for chronic itp, high bleeding risk from low platelet counts • Market expansion is supported by rising prevalence of chronic itp, expansion of biologic therapy adoption • Growth Driver: Impact Of Rising Cancer Incidence On The Growth Of The Nplate, Romiplate (Romiplostim) Market • Market Trend: Advanced Solutions Enhance Radiation Emergency Preparedness And Survival Outcomes • North America was the largest region in 2025.

What Is Covered Under Nplate, Romiplate (romiplostim) Market?

Nplate and Romiplate (romiplostim) are biologic medications classified as thrombopoietin receptor agonists. They are used to treat immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, leading to an increased risk of bleeding. Romiplostim stimulates platelet production in the bone marrow, helping to maintain a safe platelet count in patients with chronic ITP. The main patient types of nplate, romiplate (romiplostim) are pediatric patients, adult patients, and geriatric patients. It includes children and adolescents who are diagnosed with conditions that require treatment with Romiplate, such as chronic immune thrombocytopenia (ITP). Romiplate helps in stimulating platelet production, making it an important therapy for younger patients with low platelet counts. Pediatric patients may need tailored dosages and monitoring due to their developing bodies. It is used for various applications such as chronic immune thrombocytopenia, chemotherapy-induced thrombocytopenia, and other applications and it is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Nplate, Romiplate (romiplostim) Market Growth Forecast?

The nplate, romiplate (romiplostim) market size is expected to see strong growth in the next few years. It will grow to $2.03 million in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising prevalence of chronic itp, expansion of biologic therapy adoption, improved long-term safety data, growth of specialty care access, patient preference for sustained platelet control. Major trends in the forecast period include growing adoption of thrombopoietin receptor agonists, shift toward long-term itp management, increased focus on chronic autoimmune disorders, expansion of specialty hematology clinics, improved patient monitoring and dosing strategies.

Global Nplate, Romiplate (romiplostim) Market Segmentation

1) By Patient Type: Pediatric Patients, Adult Patients, Geriatric Patients 2) By Application: Chronic Immune Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Nplate, Romiplate (romiplostim) Market?

The increasing incidence of cancer is expected to propel the growth of the Nplate, Romiplate (Romiplostim) market going forward. Cancer refers to a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is driven by factors such as an aging population, environmental exposures, lifestyle choices including smoking and poor diet, genetic predispositions, and improvements in diagnostic techniques enabling earlier detection. Nplate and Romiplate (Romiplostim) stimulate platelet production via the thrombopoietin receptor, helping cancer patients particularly those undergoing chemotherapy by reducing the risk of thrombocytopenia, improving platelet counts, enhancing safety during treatment, and lowering the need for platelet transfusions. For instance, in August 2024, according to a report by the Australian Institute of Health and Welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, up from an estimated 169,000 cases in 2024, reflecting the impact of a growing population and rising cancer rates. Additionally, in 2024, cancer is expected to account for about 3 out of every 10 deaths in the country. Therefore, the increasing incidence of cancer is driving the growth of the Nplate, Romiplate (Romiplostim) industry. Rising healthcare expenditure is expected to propel the growth of the nplate, romiplate (romiplostim) market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Rising healthcare expenditure boosts Nplate and Romiplate sales by increasing access to advanced biologics like romiplostim for treating chronic conditions such as ITP. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rising healthcare expenditure is driving the nplate, romiplate (romiplostim) industry.

Key Players In The Global Nplate, Romiplate (romiplostim) Market

Major companies operating in the nplate, romiplate (romiplostim) market are Novartis AG, Amgen, Intas Pharmaceuticals

Global Nplate, Romiplate (romiplostim) Market Trends and Insights

Major companies operating in the nplate, romiplate (romiplostim) market focus on developing advanced solutions, such as administration kits, to simplify use, accelerate delivery, and improve survival outcomes for patients exposed to acute myelosuppressive doses of radiation. Administration kits provide a set of tools that allow healthcare providers to deliver Nplate (Romiplostim) quickly and accurately during radiological or nuclear emergencies. For instance, in October 2023, BARDA, a US-based government health and human services department, announced its support to develop an administration kit for Nplate (Romiplostim). Under an ongoing Project BioShield contract, BARDA procured additional doses of Nplate to strengthen preparedness for radiological emergencies. Healthcare providers administer Nplate to adult and pediatric patients, including newborns, to increase survival in cases of Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS).

Regional Insights

North America was the largest region in the nplate, romiplate (romiplostim) market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Nplate, Romiplate (romiplostim) Market?

The nplate, romiplate (romiplostim) market consists of sales of the lyophilized powder for injection, nplate 500 mcg, and nplate 125 mcg. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nplate, Romiplate (romiplostim) Market Report 2026?

The nplate, romiplate (romiplostim) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nplate, romiplate (romiplostim) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.